These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 22948997)

  • 41. Twelve-month outcomes of treatment using ranibizumab or aflibercept for neovascular age-related macular degeneration: a comparative study.
    Kim JH; Lee DW; Chang YS; Kim JW; Kim CG
    Graefes Arch Clin Exp Ophthalmol; 2016 Nov; 254(11):2101-2109. PubMed ID: 27230919
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Three-monthly intravitreal bevacizumab injections for neovascular age-related macular degeneration: short-term visual acuity results.
    Ferraz D; Bressanim G; Takahashi B; Pelayes D; Takahashi W
    Eur J Ophthalmol; 2010; 20(4):740-4. PubMed ID: 20155704
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.
    Rich RM; Rosenfeld PJ; Puliafito CA; Dubovy SR; Davis JL; Flynn HW; Gonzalez S; Feuer WJ; Lin RC; Lalwani GA; Nguyen JK; Kumar G
    Retina; 2006; 26(5):495-511. PubMed ID: 16770255
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A 1-year retrospective review of ranibizumab for naive nonsubfoveal choroidal neovascularization secondary to age-related macular degeneration.
    Arias L; Ruiz-Moreno JM; Gómez-Ulla F; Fernández M; Montero J
    Retina; 2009; 29(10):1444-9. PubMed ID: 19730163
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Treatment of neovascular age-related macular degeneration with intravitreal bevacizumab: efficacy of three consecutive monthly injections.
    Melamud A; Stinnett S; Fekrat S
    Am J Ophthalmol; 2008 Jul; 146(1):91-5. PubMed ID: 18455144
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Neovascular age-related macular degeneration treated with ranibizumab or aflibercept in the same large clinical setting: visual outcome and number of injections.
    Rasmussen A; Sander B; Larsen M; Brandi S; Fuchs J; Hansen LH; Lund-Andersen H
    Acta Ophthalmol; 2017 Mar; 95(2):128-132. PubMed ID: 27535819
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Fundus autofluorescence not predictive of treatment response to intravitreal bevacizumab in exudative age-related macular degeneration.
    Chhablani J; Kozak IR; Mojana F; Cheng L; Morrison VL; Wang H; Kim JS; Dustin L; Azen S; Freeman WR
    Retina; 2012 Sep; 32(8):1465-70. PubMed ID: 22466489
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Triamcinolone acetonide as adjunctive treatment to verteporfin in neovascular age-related macular degeneration: a prospective randomized trial.
    Chaudhary V; Mao A; Hooper PL; Sheidow TG
    Ophthalmology; 2007 Dec; 114(12):2183-9. PubMed ID: 18054638
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparison of different morphologies of choroidal neovascularization evaluated by ocular coherence tomography angiography in age-related macular degeneration.
    Tew TB; Lai TT; Hsieh YT; Ho TC; Yang CM; Yang CH
    Clin Exp Ophthalmol; 2020 Sep; 48(7):927-937. PubMed ID: 32458526
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [What can anti-VEGF therapy achieve in clinical routine? : Effectiveness of anti-VEGF therapy in patients with macular diseases in clinical routine on 1492 eyes in Austria].
    Wiesinger K; Reinelt P; Ennemoser A; Edelmayr M; Schönherr U
    Ophthalmologe; 2017 Jul; 114(7):639-645. PubMed ID: 27815675
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Intravitreal bevacizumab combined with infliximab in the treatment of choroidal neovascularization secondary to age-related macular degeneration: case report series.
    Freitas LG; Isaac DL; Tannure WT; Gabriel LA; Reis RG; Rassi AR; Freitas CA; Ávila MP
    Arq Bras Oftalmol; 2013; 76(3):180-4. PubMed ID: 23929080
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.
    Avery RL; Pieramici DJ; Rabena MD; Castellarin AA; Nasir MA; Giust MJ
    Ophthalmology; 2006 Mar; 113(3):363-372.e5. PubMed ID: 16458968
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Visual acuity outcomes in ranibizumab-treated neovascular age-related macular degeneration; stratified by baseline vision.
    Shona O; Gupta B; Vemala R; Sivaprasad S
    Clin Exp Ophthalmol; 2011 Jan; 39(1):5-8. PubMed ID: 21040311
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pegaptanib: choroidal neovascularization in patients with age-related macular degeneration and previous arterial thromboembolic events.
    Battaglia Parodi M; Di Bartolo E; Brue C; Cappello E; Furino C; Giuffrida S; Imparato M; Reibaldi M
    Eur J Ophthalmol; 2018 Jan; 28(1):58-62. PubMed ID: 29077191
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Change in choroidal thickness after intravitreal injection for treatment of neovascular age-related macular degeneration: Ranibizumab versus aflibercept.
    Kaya F
    J Fr Ophtalmol; 2017 Dec; 40(10):832-838. PubMed ID: 29113742
    [TBL] [Abstract][Full Text] [Related]  

  • 56. PROGNOSTIC VALUE OF SUBRETINAL HYPERREFLECTIVE MATERIAL IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION TREATED WITH BEVACIZUMAB.
    Pokroy R; Mimouni M; Barayev E; Segev F; Geffen N; Nemet AY; Segal O
    Retina; 2018 Aug; 38(8):1485-1491. PubMed ID: 28654630
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Treatment of choroidal neovascularization using intravitreal bevacizumab.
    Pedersen R; Soliman W; Lund-Andersen H; Larsen M
    Acta Ophthalmol Scand; 2007 Aug; 85(5):526-33. PubMed ID: 17511757
    [TBL] [Abstract][Full Text] [Related]  

  • 58. EFFECT OF INTRAOCULAR PRESSURE-LOWERING MEDICATIONS ON NEOVASCULAR AGE-RELATED MACULAR DEGENERATION TREATMENT OUTCOMES IN THE COMPARISON OF AGE-RELATED MACULAR DEGENERATION TREATMENT TRIALS.
    Rahimy E; Ying GS; Pan W; Hsu J
    Retina; 2019 Apr; 39(4):636-647. PubMed ID: 29517580
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Choroidal thickness and visual prognosis in type 1 lesion due to neovascular age-related macular degeneration.
    Hernández-Martínez P; Dolz-Marco R; Hervás-Marín D; Andreu-Fenoll M; Gallego-Pinazo R; Arévalo JF
    Eur J Ophthalmol; 2017 Mar; 27(2):196-200. PubMed ID: 27646337
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Intravitreal bevacizumab for occult choroidal neovascularization with pigment epithelium detachment in age-related macular degeneration.
    Bom Aggio F; Eid Farah M; Melo GB
    Acta Ophthalmol Scand; 2006 Oct; 84(5):713-4. PubMed ID: 16965511
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.